Annual report pursuant to Section 13 and 15(d)

Acquisitions, Investments, and Licenses - Available for Sale Investments Narrative (Details)

v3.6.0.2
Acquisitions, Investments, and Licenses - Available for Sale Investments Narrative (Details) - USD ($)
9 Months Ended 12 Months Ended
Sep. 30, 2016
Dec. 31, 2016
Dec. 31, 2015
Dec. 31, 2014
Investment [Line Items]        
Fair value   $ 4,528,000 $ 3,615,000  
Available for sale investments, fair value   4,528,000    
Gain (loss) on sale of investments   $ (2,321,000) (7,091,000) $ (167,000)
RXi        
Investment [Line Items]        
Available-for-sale investments, ownership percentage   5.00%    
Fair value   $ 300,000    
ARNO        
Investment [Line Items]        
Fair value   0    
Other Income (Expense), Net        
Investment [Line Items]        
Gain (loss) on sale of investments   0 0 1,300,000
Other Income (Expense), Net | RXi        
Investment [Line Items]        
Other-than-temporary impairment charge   400,000    
Other Income (Expense), Net | ARNO        
Investment [Line Items]        
Other-than-temporary impairment charge   $ 800,000    
Xenetic Biosciences, Inc.        
Investment [Line Items]        
Available-for-sale investments, ownership percentage   4.00%    
Fair value   $ 1,300,000    
Impairment charge on available-for-sale investments $ 3,500,000      
Chromadex Corporation        
Investment [Line Items]        
Available-for-sale investments, ownership percentage   2.00%    
ARNO        
Investment [Line Items]        
Available-for-sale investments, ownership percentage   5.00%    
Available for sale investments, fair value       600,000
ARNO | Other Income (Expense), Net        
Investment [Line Items]        
Impairment charge on available-for-sale investments       $ 1,400,000
MabVax        
Investment [Line Items]        
Available-for-sale investments, ownership percentage   4.00%    
RXi        
Investment [Line Items]        
Fair value     900,000  
Impairment charge on available-for-sale investments     $ 7,300,000